【ChiCTR2200061817】Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
ChiCTR2200061817
尚未开始
/
/
/
2022-07-03
/
/
Stroke
Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
To evaluate the most efficient clinical training dosage of powered robotic exoskeleton assisted gait training for improvement of gait parameters, walking performance, balance and health-related benefits in patients with chronic stroke.
整群随机分组
其它
Randomisation sequence to be generated by online randomisation generator
/
Institutional Development Grant
/
7
/
2022-06-20
2023-06-20
/
Participants will be recruited if they fulfill the following inclusion criteria: 1. Currently in the chronic phase of stroke (>= 6 months post stroke); 2. Able to walk with supervision; 3. Body weight equals to or is less than 100 kg; 4. There are no severe deformities, spasticity or restricted motion in the legs; 5. Able to follow verbal instructions.；
请登录查看Not cooperative or have unstable medical conditions or musculoskeletal diseases which affect mobility.；
请登录查看Caritas Institute of Higher Education
/
Caritas Institute of Higher Education的其他临床试验
- Randomized Controlled Trail: Medical Assessment and Response by Small-unmanned-aerial-system (MARS)
- Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
Caritas Institute of Higher Education的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04